What should NIH peer review look like?

Lawrence Tabak, who is spearheading the NIH's review of peer review, has read every single one of the thousands of responses submitted to the NIH last year, after the agency asked the biomedical community to weigh in on how it should linkurl:improve;http://www.the-scientist.com/blog/display/54100/ peer review. Last month, I sat down with him to talk about what he plans to do with this information. For starters, the "village vote" won't work, linkurl:Tabak;http://intramural.nidd

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Lawrence Tabak, who is spearheading the NIH's review of peer review, has read every single one of the thousands of responses submitted to the NIH last year, after the agency asked the biomedical community to weigh in on how it should linkurl:improve;http://www.the-scientist.com/blog/display/54100/ peer review. Last month, I sat down with him to talk about what he plans to do with this information. For starters, the "village vote" won't work, linkurl:Tabak;http://intramural.niddk.nih.gov/research/faculty.asp?People_ID=1560 said. "The fact that most people raised their hand about something doesn't mean that it's something that will have the most impact," he said. The NIH received more than 2,000 responses, some in the form of a statement from an institution or professional organization, each representing thousands of researchers. For now, the agency is sifting through the recommendations and will submit a list of key suggestions to NIH director Elias Zerhouni at the end of February. Tabak has some favorites: "There are several where I just sat and said, 'gee, I wish I had thought of that.'" But he won't say which recommendations he prefers. "I don't want to potentially bias the process." Still, "every comment has been instructive, at some level." Click linkurl:here;http://images.the-scientist.com/supplementary/audio/track5_edited.mp3 to listen to excerpts of my conversation with Tabak, during which he explains how he got involved in this massive undertaking. We want to know what you think. Click linkurl:here;http://www.the-scientist.com/news/display/54009/ to weigh in on some of the recommendations the NIH is considering.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies